BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20376084)

  • 1. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
    Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M
    Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084
    [No Abstract]   [Full Text] [Related]  

  • 2. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
    Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
    Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
    Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
    Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of IDH1/2 and TET2 mutations in myeloid disorders.
    Inoue S; Lemonnier F; Mak TW
    Int J Hematol; 2016 Jun; 103(6):627-33. PubMed ID: 26980223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
    Kurt H; Bueso-Ramos CE; Khoury JD; Routbort MJ; Kanagal-Shamanna R; Patel UV; Jorgensen JL; Wang SA; Ravandi F; DiNardo C; Luthra R; Medeiros LJ; Patel KP
    Am J Surg Pathol; 2018 May; 42(5):569-577. PubMed ID: 29635257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
    Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
    Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
    Molenaar RJ; Thota S; Nagata Y; Patel B; Clemente M; Przychodzen B; Hirsh C; Viny AD; Hosano N; Bleeker FE; Meggendorfer M; Alpermann T; Shiraishi Y; Chiba K; Tanaka H; van Noorden CJ; Radivoyevitch T; Carraway HE; Makishima H; Miyano S; Sekeres MA; Ogawa S; Haferlach T; Maciejewski JP
    Leukemia; 2015 Nov; 29(11):2134-42. PubMed ID: 25836588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common genetic mechanism in malignant bone marrow diseases.
    Levine RL; Carroll M
    N Engl J Med; 2009 May; 360(22):2355-7. PubMed ID: 19474434
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
    Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
    Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
    Tefferi A
    Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.
    Green A; Beer P
    N Engl J Med; 2010 Jan; 362(4):369-70. PubMed ID: 20107228
    [No Abstract]   [Full Text] [Related]  

  • 16. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Benson KL; Mesa RA
    Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
    Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
    Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
    Zhu C; Ma Y; Xu XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
    Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.